Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

Phase 3

Terminated

Conditions: Non-infectious Uveitis

Interventions: Drug: AIN457
Drug: Placebo

First Posted Date: 2010-03-19

Last Posted Date: 2016-01-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 86

Registration Number: NCT01090310

Locations: 🇬🇧
Novartis Investigative Site, York, United Kingdom

Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).

Phase 2

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: ICL670

First Posted Date: 2010-03-19

Last Posted Date: 2011-06-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 185

Registration Number: NCT01090323

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Medical College of Georgia, Augusta, Georgia, United States

and more 29 locations

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Salmeterol 50 μg
Drug: Placebo to indacaterol
Drug: Indacaterol
Drug: Placebo to salmeterol

First Posted Date: 2010-03-18

Last Posted Date: 2011-08-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 552

Registration Number: NCT01089127

Locations: 🇺🇸
Novartis Investigative Site, Richmond, Virginia, United States
🇺🇸
Novartis Investigator Site, Tacoma, Washington, United States
🇺🇸
Novartis Investigative site, Newport News, Virginia, United States

Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever

Phase 2

Completed

Conditions: Familial Mediterranean Fever

Interventions: Drug: Canakinumab

First Posted Date: 2010-03-17

Last Posted Date: 2012-05-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT01088880

Locations: 🇹🇷
Istanbul Medical Faculty, Dept of Rheumatology, Capa, Istanbul, Turkey

Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

Phase 2

Completed

Conditions: Advanced Gastric Cancer
Gastro-esophageal Junction Cancer

Interventions: Drug: AUY922
Drug: Docetaxel
Drug: Irinotecan

First Posted Date: 2010-03-10

Last Posted Date: 2020-12-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 68

Registration Number: NCT01084330

Locations: 🇺🇸
University of California at Los Angeles Dept. of UCLA (4), Los Angeles, California, United States
🇺🇸
Horizon Oncology Center, Lafayette, Indiana, United States
🇺🇸
Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology, Dallas, Texas, United States

and more 5 locations

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma

Phase 2

Completed

Conditions: Relapsed and Bortezomib Refractory Multiple Myeloma
Refractory Multiple Myeloma
Multiple Myeloma in Relapse

Interventions: Drug: panobinostat
Drug: bortezomib
Drug: dexamethasone

First Posted Date: 2010-03-10

Last Posted Date: 2017-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 55

Registration Number: NCT01083602

Locations: 🇺🇸
Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst., Atlanta, Georgia, United States
🇺🇸
Duke University Medical Center Dept. of DUMC (4), Durham, North Carolina, United States
🇺🇸
MD Anderson Cancer Center/University of Texas MD Anderson CC, Houston, Texas, United States

and more 10 locations

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

Phase 3

Completed

Conditions: Treatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis Patients

Interventions: Drug: TOBI
Drug: Placebo

First Posted Date: 2010-03-08

Last Posted Date: 2016-07-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 50

Registration Number: NCT01082367

Locations: 🇨🇭
Novartis Investigative Site, Zürich, Switzerland

Assessment of Aliskiren/Amlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension

Phase 2

Terminated

Conditions: Ankle Edema
Hypertension

Interventions: Drug: Aliskiren/amlodipine
Drug: Amlodipine
Drug: Placebo to Aliskiren/amlodipine
Drug: Placebo to Amlodipine

First Posted Date: 2010-03-04

Last Posted Date: 2011-12-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT01080768

Locations: 🇳🇱
Novartis Investigative Site, Wildervank, Netherlands

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.

Phase 3

Completed

Conditions: Acute Gout

Interventions: Drug: Canakinumab 150 mg
Drug: Triamcinolone acetonide 40 mg
Drug: Placebo to canakinumab
Drug: Placebo to triamcinolone acetonide

First Posted Date: 2010-03-03

Last Posted Date: 2014-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 226

Registration Number: NCT01080131

Locations: 🇺🇸
Crest Clinical Trials, Santa Ana, California, United States
🇺🇸
Rheumatic Disease Clinical Research Center, Llc, Houston, Texas, United States
🇺🇸
Rochester clinical Research, San Diego, California, United States

and more 92 locations

Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients

Phase 3

Completed

Conditions: Renal Interstitial Fibrosis

Interventions: Drug: Certican®
Drug: Neoral
Drug: Myfortic
Drug: Simulect®
Drug: Corticosteroids

First Posted Date: 2010-03-02

Last Posted Date: 2014-03-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 194

Registration Number: NCT01079143

Locations: 🇫🇷
Novartis Investigative Site, Vandoeuvre Les Nancys, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy